The use of granulocyte colony-stimulating factor to deliver four cycles of ifosfamide and epirubicin every 14 days in women with advanced or metastatic breast cancer.

Twenty patients with locally advanced or metastatic breast cancer were treated with four cycles of ifosfamide/mesna 5 g m-2 and epirubicin 60 mg m-2 every 14 days with granulocyte colony-stimulating factor (G-CSF, Filgrastim). Complete remission occurred in six out of the 20 patients (30%, 95% confi...

Descripción completa

Detalles Bibliográficos
Autores principales: Lind, M. J., Gumbrell, L., Cantwell, B. M., Millward, M. J., Simmonds, D., Proctor, M., Chapman, F., McCann, E., Middleton, I., Calvert, A. H.
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 1995
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2033646/
https://www.ncbi.nlm.nih.gov/pubmed/7533518

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2033646/
https://www.ncbi.nlm.nih.gov/pubmed/7533518

Ejemplares similares